A contributing factor to these outcomes was the significantly lower infiltration of CD8+ T cells in patients with KEAP1 mutations, particularly in endometrial cancer, breast cancer, bladder cancer, colorectal cancer, lung adenocarcinoma, and lung squamous cell carcinoma, with the lowest levels observed in lung adenocarcinoma [113]. This evidence concerns the gene CD8A and breast cancer.